Key result
Ziprasidone showed no significant difference in the 1-year risk of sudden cardiac death compared to olanzapine.
Why the study?
Does ziprasidone alter the risk of sudden death compared to olanzapine in real-world use?
RCT
Does ziprasidone alter the risk of sudden death compared to olanzapine in real-world use?
Answers are grounded in this paper and cite their sources.
Readjudication of fatal events using ICD-10 criteria confirmed no significant difference in the 1-year risk of sudden cardiac death between ziprasidone and olanzapine, highlighting the methodological challenges of missing clinical details in real-world fatal events.
PURPOSE: The Ziprasidone Observational study of car DIAC Outcomes (ZODIAC), a large simple trial comparing ziprasidone versus olanzapine in real-world use, showed no difference in risk of sudden death. Upon the request of the US Food and Drug Administration, 205 fatal events were readjudicated applying ICD-10 coding rules for sudden death. METHODS: A readjudication committee coded three domains (witness to death, time of symptom onset to death, and most likely cause of death) for use within algorithms consistent with ICD-10 rules. Relative risks (RR) and corresponding 95%CI were calculated for persons randomized to ziprasidone versus olanzapine, comparing 1-year incidence of sudden death, using multiple definitions. RESULTS: Data on symptom onset to death and diagnosis of specific cardiac arrhythmias required by the ICD-10 rules were often lacking. Sensitivity analyses were conducted to explore the impact of cases suggestive of cardiac origin but missing data required by ICD-10 sudden death codes. Overall, the readjudicated data matched the study's initial findings, with no significant difference in 1-year mortality between ziprasidone and olanzapine for sudden death not otherwise specified and sudden cardiac death (R96.0 or R96.1 or I46.1; RR = 1.11, 95%CI 0.45- 2.77). CONCLUSIONS: After outcome readjudication, ZODIAC found no difference in the risk of sudden death among those randomized to ziprasidone versus olanzapine. However, unlike hospital-based studies, fatal events in general population studies often occur outside hospital and often lack the clinical detail needed for the exact determination of symptom onset and event. Epidemiological evaluations of sudden death need to consider the limitations of the available data.
No takes yet. Share an insight, caveat, or question.
Geier et al. (2011) reported an RCT. Ziprasidone vs. Olanzapine was evaluated on Sudden death not otherwise specified and sudden cardiac death (R96.0 or R96.1 or I46.1) (RR 1.11, 95% CI 0.45-2.77). Ziprasidone showed no significant difference in the 1-year risk of sudden cardiac death compared to olanzapine.
Synapse has enriched 10 related papers. Consider them for comparative context: